Over the past 20 years, several innovative therapies have been implemented in the treatment of lung cancer that have had reported survival benefits in clinical trials. Whether these improvements translate into the clinic setting has not been studied yet. We retrospectively analyzed all patients consecutively treated at Institute Curie for metastatic lung cancer. Diagnosis date was used to define three periods, based on the approvals of novel treatment strategies in the first-line setting, including targeted therapies in 2010 and immunotherapy in 2018. Endpoints included Overall survival (OS), survival rate of 2 years and 5 years, and a conditional survival rate of 2 years (if still alive at 6 months from treatment initiation). A total of 673 patients were identified for Period 1—2000 to 2009, 752 for Period 2—2010 to 2017, and 768 for Period 3—2018 to 2020. Median OS in the whole cohort was 11.1, 15.5, and 16.2 months, respectively. Median OS for patients with NSCLC or SCLC was 11.2, 17.2, and 18.2 months, or 10.9, 11.7, and 11.2 months, respectively. The two-year conditional survival was more favorable for NSCLC than SCLC patients. Outcomes were statistically higher for women as compared to men in all periods and all subgroups. Survival of patients with metastatic lung cancer has improved over the past 20 years, mostly in NSCLC, along with the implementation of novel treatment strategies.
过去20年间，多种创新疗法已应用于肺癌治疗，临床试验中显示出生存获益。但这些改善能否转化为临床实践尚未得到研究。我们回顾性分析了居里研究所连续收治的所有转移性肺癌患者。根据一线治疗新策略的获批时间（包括2010年靶向治疗和2018年免疫治疗），以确诊日期划分三个时期。研究终点包括总生存期（OS）、2年及5年生存率，以及治疗开始后6个月仍存活患者的2年条件生存率。2000-2009年（时期1）共纳入673例患者，2010-2017年（时期2）752例，2018-2020年（时期3）768例。全队列中位OS分别为11.1、15.5和16.2个月。非小细胞肺癌（NSCLC）与小细胞肺癌（SCLC）患者中位OS分别为11.2/17.2/18.2个月与10.9/11.7/11.2个月。NSCLC患者的两年条件生存率优于SCLC患者。所有时期及各亚组中，女性患者的生存结局均显著优于男性。随着新型治疗策略的应用，转移性肺癌患者生存期在过去20年间得到改善，其中NSCLC患者获益尤为显著。
Real-World Survival Impact of New Treatment Strategies for Lung Cancer: A 2000–2020 French Cohort
肿瘤(癌症)患者之家